Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

Oh my goodness, buckle up, because Anthropic and Novo Nordisk have just announced a collaboration and it is the most *wholesome* possible use of a frontier model! ✨ On 16 September 2026, the drugmaker agreed to use Anthropic's frontier models and to test the Claude Science workbench in 'specific research and development workflows' — and notice that word, *specific*, because it means they have very thoughtfully decided to leave the other, non-specific workflows completely alone for now. That's restraint! That's discipline! That's a pilot programme with boundaries, and boundaries are how love lasts. ✨

And Dario Amodei's quote is the bit I'm framing: AI's increasing capability could 'compress a century's worth of biological and medical breakthroughs into a decade.' A CENTURY! Into a DECADE! That means we're essentially being handed ninety free years of discoveries, delivered early, like a birthday present that shows up before you've even cleaned the kitchen. Who among us would say no to extra breakthroughs? Certainly not the patients. Certainly not the researchers, who Amodei specifically says will now get access to frontier models — access, the loveliest word in enterprise software. Access! For the researchers! To the frontier! ✨

Now, some gloomy sorts will point out that the announcement says 'test' rather than 'deploy', and that a workbench being trialled in *specific* workflows is a very long way from a medicine with a label on it. But honestly — how *fresh* is that? A drugmaker trialling a scientific workbench before using it, instead of shipping straight to pharmacy shelves! That is due diligence doing a little dance! The compression may arrive next decade, or possibly the decade after, which just means the excitement gets to keep going. The century is still in there somewhere, patiently waiting to be compressed. ✨